October 2020 Volume 16, Issue 9
Volume 16, Issue 9 | October 2020
October 2020
In this Issue
Discovery
Translational science comes to the fore
Protease inhibitors might help to manage COVID-19Lodo Therapeutics acquires Conifer Point
Lodo expands AI/ML capabilities and gains exclusive rights to suite of cheminformatics technologiesJnana and Roche investigate SLCs
Innovative approach for modulating cellular metabolism could treat a variety of diseasesUnderstanding lupus one cell at a time
JAX team finds distinctive interferon gene expression signature across wide variety of blood cells
RNA to repair a heart
Scripps team identifies molecule that can bind to RNA to increase VEGF-A productionPreclinical
Down-regulating PTB
One-time Parkinson’s treatment generates new neuronsSecond-gen COVID vaccine in development
OSE Immunotherapeutics leverages cancer vaccine to develop CoVepiTMSCs demonstrate efficacy in preclinical lung disease study
Cynata Therapeutics cites positive data in rodent model of IPF
Video: Riding the Wave
Wave Life Sciences releases preclinical data for ADAR editing and C9orf72 programResearch & Development
Better health with humanin?
USC-led study says humanin could lower risk for Alzheimer’sUtrecht and Bruker team up on mass spec methods
Crosslinking mass spectrometry can now use PhoX Crosslinker and TIMS/PASEF methodsGoing after glioblastoma
Purdue team looks to harness natural killer cells to fight cancerContract Services
A bottleneck to hold up ATMP progress?
GlobalData says few CMOs are equipped to manufacture cell and gene therapiesMaravai expands again to meet mRNA therapy and vaccine demand
Company expands TriLink BioTechnologies CleanCap capacity and adds new plasmid DNA manufacturingClinical Trials
Adjunctive achievement
OCD drug candidate posts good Phase 2/3 study resultsOne and done for HIV?
AGT begins Phase 1 clinical trial on potential cure for HIV/AIDSOPTIMAL trial points to new option for acromegaly treatment
Phase 3 data of oral octreotide meets all primary and secondary endpointsDiagnostics
A 10-minute test for COVID
Todos announces positive data for new point-of-care saliva-based testAdvancing a SARS-CoV-2 antigen test
Avacta and LSTM collaborate to clinically validate saliva-based rapid coronavirus testWellcome Sanger updates DECIPHER
Institute also working on genetic prediction of blood diseases and ramping up COVID-19 researchDiscovering pancreatic cancer earlier
Collaborative studies at University of Missouri show promiseBusiness & Government Policy
J&J seeks immune momentum with Momenta
Pharma giant acquires Momenta for $6.5B, setting sights on autoantibody-driven disease marketOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsQ&A: Tackling developmental disorders through the ERK pathway
DDN spoke with Dr. Michael Snape, chief scientific officer of AMO Pharma, to discuss drugs that target the ERK signaling cascade, and how these drugs might be able to treat a range of developmental disordersCommentary
Editor’s Focus: Nearing year’s end and looking forward
DDN is evolving in all its forms, from print to online, and we look forward to unveiling it all soonOut of order: Sausage-making
Science is knowing you never have a complete answer and challenging any answer that arises. To the general public, however, this uncertainty rankles at a minimum and terrifies in its extreme.Guest Commentary: RNA-seq in preclinical research and drug discovery--digging deep for insights
RNA-seq offers a comprehensive method for studying differential gene expression and changing levels of noncoding RNAs at both the single-cell and bulk sequencing levels, thus offering a powerful arsenal of investigative tools for understanding the molecular basis of disease and for the discovery and testing of new treatment optionsSpecial Reports
Special Report on Metabolic Disease: Intercepting diabetes
Researchers are increasingly targeting autoimmunity rather than hyperglycemia as they search for better ways to treat type 1 diabetes
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
